Since overexpression of FGFRs contributes to advanced HCC tumorigenesis, metastasis, and poor prognosis [13,14,15], and is postulated to be upregulated as a mechanism of resistance to anti-VEGF treatment, combination therapies designed to block FGFR/VEFGR signaling cascades may represent an alternative treatment for HCC patients. This evidence concerns the gene VEGFA and hepatocellular carcinoma.